Beacon Topco completes Barinthus Bio acquisition; launches $15M share tender offer

BEACON TOPCO, INC.

Acquisition of Barinthus Biotherapeutics closed via UK scheme of arrangement effective Sept 9, 2026; Barinthus now wholly-owned subsidiary.
Cash tender offer launched Sept 15, 2026 to buy up to $15M of Beacon Topco common stock at $6.6609 per share, net to seller, no interest.
Amended and restated certificate of incorporation adopted effective Sept 9, 2026; amended and restated bylaws effective Sept 8, 2026.
Merger Agreement dated Sept 29, 2025, as amended Feb 22, 2026, governed the transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.